Get started
Author

Yurong Yan

Observed name: Yan, Yurong
OpenAlex ID: A5044948676
Proposed risk‐scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma
2022 · Peiyu Yang, Haimin Chen, et al. · American Journal of Hematology · 18
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study
2024 · Yingjie Zhang, Xinyue Liang, et al. · Journal of Hematology & Oncology · 8
Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma
2022 · Peiyu Yang, Weiling Xu, et al. · American Journal of Hematology · 7
PDF
The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study
2024 · Dong Liang, Yurong Yan, et al. · BMC Cancer · 6
PDF
Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis
2024 · Weiling Xu, Xinyue Liang, et al. · Clinical Medicine · 6
Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
2025 · Dong Liang, Yurong Yan, et al. · Hematological Oncology · 3
PDF
More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma
2023 · Mengru Tian, Xinyue Liang, et al. · Annals of Hematology · 2
Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study
2025 · Dong Liang, Yurong Yan, et al. · Annals of Medicine
Author response for "Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study"
2025 · Liang, Dong, Yan, Yurong, et al.
A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma
2022 · Fengyan Jin, Peiyu Yang, et al. · Blood
Works count: 12
Citation count: 50
H-index: 5
I10-index: 1
Year
Topic
Type